Added to YB: 2026-10-07
Pitch date: 2026-10-02
NKTR [bullish]
Nektar Therapeutics
-13.29%
current return
Author Info
Kelin Research shares independent research on listed life sciences companies. I work from primary sources, clinical data and back-of-the-envelope valuation to answer three questions: what does the science say, what is the market pricing in, and what would prove or kill the thesis? Sign up for the newsletter.
Company Info
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
Market Cap
$1.4B
Pitch Price
$43.50
Price Target
66.00 (+75%)
Dividend
N/A
EV/EBITDA
-7.43
P/E
-6.53
EV/Sales
16.36
Sector
Biotechnology
Category
value
Nektar Therapeutics (NKTR): A Messy Durability Story (Update / Flash Note)
NKTR (exited position): Nektar’s rise from $23 to $47 and lack of catalysts before the next AD update in Q1 2027 support exiting and potentially returning lower. AA data showed 5/27 rezpeg-treated extension entrants at the cited durability threshold; shifting denominators weakened confidence, though rezpeg retained activity and possible off-drug durability. The stated $66 target implies ~40% upside from $47 but is due for conservative reassessment; napkin math at a 65% discount rate and 1.5x peak sales suggests AD alone backstops valuation.
Read full article (3 min)